Site search
2897 results for '' found
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
/
Evaluation of the RibFix™ Advantage Rib Fixation System for Surgical Repair of Rib Fractures (Trial Not Registered)
Evaluation of the RibFix™ Advantage Rib Fixation System for Surgical Repair of Rib Fractures (Trial Not Registered)
/
Re-EValuating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill (REVISE) trial (NCT03374800)
Re-EValuating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill (REVISE) trial (NCT03374800)
/
Unravelling the reversibility of pulmonary vascular disease in HFpEF, aortic stenosis and CTEPH after intervention: the REVERS-PVD study (Trial Not Registered)
Unravelling the reversibility of pulmonary vascular disease in HFpEF, aortic stenosis and CTEPH after intervention: the REVERS-PVD study (Trial Not Registered)
/
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s
/
Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure (RESPONDER-HF) (NCT05425459)
Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved EF Heart Failure (RESPONDER-HF) (NCT05425459)
/
RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)
RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)
/
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
/
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
/